RU2017107033A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017107033A3 RU2017107033A3 RU2017107033A RU2017107033A RU2017107033A3 RU 2017107033 A3 RU2017107033 A3 RU 2017107033A3 RU 2017107033 A RU2017107033 A RU 2017107033A RU 2017107033 A RU2017107033 A RU 2017107033A RU 2017107033 A3 RU2017107033 A3 RU 2017107033A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037374P | 2014-08-14 | 2014-08-14 | |
| US62/037,374 | 2014-08-14 | ||
| PCT/US2015/045071 WO2016025721A1 (en) | 2014-08-14 | 2015-08-13 | Methods of treating depression using nmda modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017107033A RU2017107033A (ru) | 2018-09-14 |
| RU2017107033A3 true RU2017107033A3 (https=) | 2019-02-12 |
Family
ID=55304631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017107033A RU2017107033A (ru) | 2014-08-14 | 2015-08-13 | Способы лечения депрессии с применением модуляторов nmda |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20170296616A1 (https=) |
| EP (1) | EP3180015A4 (https=) |
| JP (2) | JP2017524721A (https=) |
| KR (1) | KR20170040351A (https=) |
| CN (1) | CN106659763A (https=) |
| AU (2) | AU2015301650A1 (https=) |
| BR (1) | BR112017002930A2 (https=) |
| CA (1) | CA2957937A1 (https=) |
| CL (1) | CL2017000378A1 (https=) |
| CO (1) | CO2017002356A2 (https=) |
| IL (1) | IL250557A0 (https=) |
| MX (1) | MX2017002052A (https=) |
| PH (1) | PH12017500275A1 (https=) |
| RU (1) | RU2017107033A (https=) |
| SG (2) | SG11201701134XA (https=) |
| UA (1) | UA123623C2 (https=) |
| WO (1) | WO2016025721A1 (https=) |
| ZA (1) | ZA201701526B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018530593A (ja) * | 2015-10-16 | 2018-10-18 | ノースウェスタン ユニバーシティ | 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| US11358935B2 (en) | 2016-11-28 | 2022-06-14 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| JP2021512857A (ja) * | 2017-11-10 | 2021-05-20 | ノーレックス インコーポレイテッド | Ｎｍｄａ受容体アゴニストの投与方法 |
| CA3084437A1 (en) | 2017-12-05 | 2019-06-13 | Naurex Inc. | Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| PL2485751T3 (pl) * | 2009-10-05 | 2014-10-31 | Univ Northwestern | GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
-
2015
- 2015-08-13 RU RU2017107033A patent/RU2017107033A/ru not_active Application Discontinuation
- 2015-08-13 AU AU2015301650A patent/AU2015301650A1/en not_active Abandoned
- 2015-08-13 JP JP2017507973A patent/JP2017524721A/ja active Pending
- 2015-08-13 BR BR112017002930A patent/BR112017002930A2/pt not_active IP Right Cessation
- 2015-08-13 SG SG11201701134XA patent/SG11201701134XA/en unknown
- 2015-08-13 MX MX2017002052A patent/MX2017002052A/es unknown
- 2015-08-13 UA UAA201702145A patent/UA123623C2/uk unknown
- 2015-08-13 WO PCT/US2015/045071 patent/WO2016025721A1/en not_active Ceased
- 2015-08-13 CN CN201580043626.3A patent/CN106659763A/zh active Pending
- 2015-08-13 KR KR1020177006761A patent/KR20170040351A/ko not_active Ceased
- 2015-08-13 CA CA2957937A patent/CA2957937A1/en not_active Abandoned
- 2015-08-13 US US15/503,840 patent/US20170296616A1/en not_active Abandoned
- 2015-08-13 SG SG10201810016XA patent/SG10201810016XA/en unknown
- 2015-08-13 EP EP15832514.2A patent/EP3180015A4/en not_active Withdrawn
-
2017
- 2017-02-12 IL IL250557A patent/IL250557A0/en unknown
- 2017-02-14 PH PH12017500275A patent/PH12017500275A1/en unknown
- 2017-02-14 CL CL2017000378A patent/CL2017000378A1/es unknown
- 2017-03-01 ZA ZA2017/01526A patent/ZA201701526B/en unknown
- 2017-03-10 CO CONC2017/0002356A patent/CO2017002356A2/es unknown
-
2020
- 2020-04-23 JP JP2020076468A patent/JP2020128391A/ja active Pending
- 2020-05-15 AU AU2020203165A patent/AU2020203165A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| UA123623C2 (uk) | 2021-05-05 |
| IL250557A0 (en) | 2017-03-30 |
| JP2017524721A (ja) | 2017-08-31 |
| JP2020128391A (ja) | 2020-08-27 |
| PH12017500275A1 (en) | 2017-07-03 |
| EP3180015A4 (en) | 2018-02-14 |
| EP3180015A1 (en) | 2017-06-21 |
| US20170296616A1 (en) | 2017-10-19 |
| KR20170040351A (ko) | 2017-04-12 |
| CL2017000378A1 (es) | 2017-11-03 |
| MX2017002052A (es) | 2018-08-15 |
| AU2020203165A1 (en) | 2020-06-04 |
| BR112017002930A2 (pt) | 2017-12-05 |
| CN106659763A (zh) | 2017-05-10 |
| RU2017107033A (ru) | 2018-09-14 |
| WO2016025721A1 (en) | 2016-02-18 |
| CA2957937A1 (en) | 2016-02-18 |
| ZA201701526B (en) | 2018-05-30 |
| AU2015301650A1 (en) | 2017-03-23 |
| SG10201810016XA (en) | 2018-12-28 |
| SG11201701134XA (en) | 2017-03-30 |
| CO2017002356A2 (es) | 2017-06-09 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210811 |